| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Nektar Therapeutics (NKTR) has 8 insiders with recent SEC Form 4 filings, including 0 buys and 14 sells. NKTR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 75.9K | $4.92M | - | |
| Other | 21.6K | $1.40M | - | |
| Other | 15.4K | $1.00M | -5,538 | |
| Dir | 8.0K | $518.7K | - | |
| Dir | 8.0K | $518.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 9, 2018 | Hora Maninder | SVP Pharma Dev &Mfg Ops | Sale+OE | 29,498 | $102.81 | $3,032,764.90 | -15.5% | |
| Apr 6, 2018 | Greer R Scott | Director | Sale+OE | 30,000 | $92.22 | $2,766,600.00 | -18.7% | |
| Apr 6, 2018 | Chess Robert84 | Director | Sale+OE | 25,000 | $92.14 | $2,303,600.00 | -4.4% | |
| Apr 5, 2018 | Lingnau Lutz | Director | Sale+OE | 30,000 | $101.74 | $3,052,200.00 | -52.2% | |
| Mar 7, 2018 | Kuebler Christopher A58 | Director | Sale+OE | 40,000 | $97.60 | $3,903,914.00 | -33.1% | |
| Mar 7, 2018 | Nicholson John | SVP &Chief Operating Officer | Sell | 220,144 | $99.27 | $21,854,264.80 | -33.6% | |
| Feb 16, 2018 | Labrucherie Gil M84 | SVP &Chief Financial Officer | Sell | 3,477 | $82.94 | $288,382.38 | -3.4% | |
| Feb 16, 2018 | Thomsen Jillian B.86 | SVP &Chief Accounting Officer | Sell | 2,545 | $82.94 | $211,082.30 | -3.6% | |
| Feb 16, 2018 | Robin Howard W58 | President &CEO | Sell | 12,788 | $82.94 | $1,060,636.72 | -5.1% | |
| Feb 16, 2018 | Nicholson John | SVP &Chief Operating Officer | Sell | 4,879 | $82.94 | $404,664.26 | -1.2% |